Shares of Conatus Pharmaceuticals (CNAT) tumbled as much as 40% Friday, closing the day at $6.19 per share. The company reported top line data on a phase 2 trial testing the drug Emricasan in patients with acute chronic liver failure — ACLF — and organ impairment. The drug showed an excellent reduction of key biomarkers…
Over the last five trading sessions, Video Game stocks mostly witnessed a mixed trend. While NetEase, Inc. (NTES – Snapshot Report) and Electronic Arts (EA – Analyst Report) gained momentum, Glu Mobile, Inc. (GLUU – Snapshot Report) and Zynga, Inc. (ZNGA – Snapshot Report) tumbled. Some of the major stories that grabbed headlines over the past week were the launch of Call of Duty:…
Ding! Ding! Ding! Signs of a major market top keep piling on. Pimco provides the latest bell-ringer with launch of 7 new equity strategies. Please consider Pimco Plans a Push Into Stocks. Long known as a bond powerhouse, Pacific Investment Management Co. is once again attempting an expansion into stock mutual funds. The Newport Beach, Calif.-based…
NephroGenex Inc. (NASDAQ:NRX) has announced that the Company has received positive Scientific Advice from the European Medicines Agency (EMA) regarding their Phase 3 program with Pyridorin® in diabetic nephropathy that has been accepted by the U.S. Food and Drug Administration under a Special Protocol Assessment. The EMA had cleared that the current Phase 3 program could…
The deep plunge in oil prices has been the key market theme over the past couple of months. The almost $50 a barrel share decline in oil prices has created many winners and losers in the markets. Transports like Airlines have soared while the collapse in crude has decimated much of the exploration and production…
“We who are born into this age of freedom and independence and the self must undergo this loneliness. It is the price we pay for these times of ours.” – Natsume Sôseki “The issue isn’t just jobs. Even slaves had jobs. The issue is wages.” – Jim Hightower The headline ‘Jobs Number’ came in…
2014 was a lousy year for global value investors. Cheap markets, as measured by the cyclically-adjusted price/earnings ratio (“CAPE”) got even cheaper, while expensive markets got even pricier. (Note: the CAPE takes a ten-year average of earnings as a way of smoothing out the economic cycle and allowing for better comparisons over time.) I expect…
Let me preface this post by saying this is really more of a curiosity than anything actionable but I found it rather interesting. My last post focused on the possibility of 2015 being another 1999. This post looks at one indicator that may suggest 2015 rhymes better with 2000. There has been a fair amount of…
Quite a day and quite a week… and quite an ugly close… The S&P – closing down 0.5% – had the worst first week of the year since 2009. Stocks ended the day red (but don’t blame the dreadful labor data under the surface because headlines were great – instead blame France!)… with an ugly…
Over the past week the majority of our core market health indicators fell. Most significantly was our core measure of risk. It bounced back and forth between positive and negative, but managed to eek out a win and stay above zero near the close on Friday. As a result, there are no changes to our…
